Trial
NCT05632354
GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Pfizer
Collaborators
—
Condition
Sickle Cell Disease
Intervention
Osivelotor
Why stopped
Study terminated as data obtained from this non-placebo-controlled trial may not be informative for the interpretation of the benefits and risks of osivelotor
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-19